Codexis, Inc. (NASDAQ:CDXS) Sees Significant Growth in Short Interest

Codexis, Inc. (NASDAQ:CDXS) saw a large growth in short interest in the month of March. As of March 15th, there was short interest totalling 4,570,000 shares, a growth of 50.8% from the February 28th total of 3,030,000 shares. Based on an average trading volume of 843,500 shares, the short-interest ratio is presently 5.4 days. Currently, 5.7% of the shares of the stock are sold short.

Institutional Trading of Codexis

Large investors have recently bought and sold shares of the stock. Summit Investment Advisors Inc. grew its holdings in shares of Codexis by 81.4% in the 4th quarter. Summit Investment Advisors Inc. now owns 8,428 shares of the biotechnology company’s stock worth $40,000 after purchasing an additional 3,783 shares during the last quarter. Wolverine Trading LLC bought a new stake in Codexis during the fourth quarter worth about $56,000. Fiduciary Trust Co acquired a new stake in shares of Codexis during the fourth quarter worth approximately $65,000. Intech Investment Management LLC bought a new position in shares of Codexis in the third quarter valued at approximately $66,000. Finally, Group One Trading LLC bought a new position in shares of Codexis in the fourth quarter valued at approximately $73,000. 78.54% of the stock is currently owned by institutional investors.

Codexis Price Performance

Shares of Codexis stock opened at $2.81 on Friday. The firm has a market cap of $232.77 million, a P/E ratio of -3.23 and a beta of 2.12. The firm’s 50-day simple moving average is $3.71 and its 200-day simple moving average is $3.94. Codexis has a twelve month low of $2.43 and a twelve month high of $6.08. The company has a debt-to-equity ratio of 0.39, a quick ratio of 3.15 and a current ratio of 3.21.

Codexis (NASDAQ:CDXS) last released its quarterly earnings data on Thursday, February 27th. The biotechnology company reported ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.09). Codexis had a negative net margin of 96.35% and a negative return on equity of 71.56%. The company had revenue of $21.46 million for the quarter, compared to analyst estimates of $27.41 million. As a group, research analysts expect that Codexis will post -0.77 EPS for the current fiscal year.

About Codexis

Codexis, Inc discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes.